Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients

Inclusion Criteria: 1. Adult men (between 40 and 70 years of age). 2. T2DM defined according to ADA or HAS criteria, evolving for more than 6 months, may be : - Not complicated * Complicated by diabetic retinopathy and/or diabetic nephropathy (creatinine clearance \> 60 ml/min) and/or peripheral arterial disease and/or ischemic heart disease and/or stroke. - With dyslipidemia (LDLc \> 1.90) and/or a history of past or active smoking. * Balanced with HbA1c \< 8% according to patient's personalized objectives, or unbalanced with HbA1c \> 9%. * Treated with insulin therapy (single or multi-injections) or not. - Whose treatment includes at least one iSGLT2. 3. Member of 'Sécurité Sociale" Exclusion Criteria: 1. Patient already included in another study. 2. Patient in a particular situation judged incompatible with the study by the investigator. 3. Patient living in a department other than Alpes-Maritimes or Var. 4. Patient refusing to give consent. 5. Patient deprived of liberty by administrative or judicial decision, under guardianship or curatorship. 6. Patient with decompensated hepatic cirrhosis (Child C and above, score 10 to 15 points). 7. Patients with chronic kidney disease (from stage 3, i.e. GFR \< 59 ml/min/1.73 m2). 8. Patient with a recent fracture (within the last 3 months). 9. Patient treated with AVK or biphosphonates. 10. Patient with known, treated osteoporosis. 11. Patient with unsupplemented vitamin D deficiency. 12. Patient with active cancer. 13. Patient with an active inflammatory pathology.